Description

BSE Surveillance sought clarifications from Amara Raja Energy & Mobility Ltd and Dr Reddys Laboratories Ltd regarding news articles. Reply received from Amara Raja; Dr Reddys reply is still awaited.

Summary

BSE’s Surveillance Department (DOSS) sought clarifications from two listed companies regarding news articles appearing in newspapers, websites, and television channels. The exchange issued this notice (20260423-24) to inform members and investors about the accuracy of such reports. Amara Raja Energy & Mobility Ltd has submitted its reply, while Dr Reddys Laboratories Ltd’s response is still awaited.

Key Points

  • BSE Surveillance proactively sought clarifications from companies to verify news articles circulating in media.
  • Amara Raja Energy & Mobility Ltd (Scrip Code: 500008) has submitted its clarification reply (referenced from moneycontrol.com article).
  • Dr Reddys Laboratories Ltd (Scrip Code: 500124) has not yet submitted its reply (referenced from cnbctv18.com article).
  • The notice was issued by Deputy Vice President Sanjay Jain and Manager Shreya Ghose from the Surveillance department.

Regulatory Changes

No regulatory changes are introduced by this circular. It is a standard surveillance notice informing the market of clarification requests sent to listed companies.

Compliance Requirements

  • Dr Reddys Laboratories Ltd (Scrip Code: 500124) is expected to submit its clarification to BSE regarding the news article published on cnbctv18.com.
  • No action is required from members or investors at this stage.

Important Dates

  • Notice Date: 23 April 2026
  • No explicit deadline stated for Dr Reddys’ pending reply.

Impact Assessment

This is a low-impact informational notice. Investors holding or tracking Amara Raja Energy & Mobility Ltd (500008) may refer to the attached reply for clarification on the related news article. Those tracking Dr Reddys Laboratories Ltd (500124) should note that a clarification is pending and watch for a subsequent BSE notice once the reply is received. No trading restrictions or regulatory actions are indicated.

Impact Justification

Routine surveillance disclosure informing members of clarification status from two companies on circulating news articles. No regulatory changes or trading restrictions are involved; one reply is pending.